Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OAKS: Pegcetacoplan in Geographic Atrophy
NCT03525613Phase 3Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Jun 2021
- Modality
- PEGylated Peptides
- Countries
- 14
01
Overview
A Phase 3 trial of pegcetacoplan in geographic atrophy (GA), sponsored by Apellis Pharmaceuticals. Started Aug 2018; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT03525613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525613.